Paeds Vivas · mental-behavioural-and-psychosomatic
Early-onset psychosis and mania — branching viva
Branching viva on the psychosis-mania gate: distinguishing psychosis, mania and mimics, organic exclusion, duration of untreated psychosis, cannabis risk, TEOSS and the paediatric mania trials, and antipsychotic metabolic monitoring.
On this page
Study tools
Target exams
Opening
Examiner: A 15-year-old boy is brought in believing classmates implanted a chip in his head, has not slept for four nights, and smokes high-potency cannabis daily. Walk me through your approach from the moment you meet him. [2]
Candidate: He is a medical patient first and a psychiatric patient second. I run the gate in order: assess, distinguish, exclude danger, refer early and treat. I greet him first, set a joint agenda, and secure time alone with conditional confidentiality stated aloud. Because a psychotic young person is an unreliable sole historian, I gather collateral from family and school on onset, course, function, family psychiatric history, substance use and trauma. I perform a mental-state examination, run HEEADSSS with focused probes, and screen suicide risk with plan, intent and means — then exclude organic disease before any label. [2]
References9ShowHide
- [1]Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study. American Journal of Psychiatry, 2008.PMID 18794207
- [2]McClellan J, Stock S Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. Journal of the American Academy of Child and Adolescent Psychiatry, 2013.PMID 23972700
- [3]Cannon TD, Cadenhead K, Cornblatt B, Woods SW, Addington J, et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Archives of General Psychiatry, 2008.PMID 18180426
- [4]Penttilä M, Jääskeläinen E, Hirvonen N, Isohanni M, Miettunen J Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis. British Journal of Psychiatry, 2014.PMID 25252316
- [5]Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet, 2007.PMID 17662880
- [6]Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ, 2002.PMID 12446537
- [7]Geller B, Luby JL, Joshi P, Wagner KD, Emslie G, et al. A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. Archives of General Psychiatry, 2012.PMID 22213771
- [8]Wagner KD, Kowatch RA, Emslie GJ, Findling RL, Wilens TE, et al. A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. American Journal of Psychiatry, 2006.PMID 16816222
- [9]Tohen M, Kryzhanovskaya L, Carlson G, Delbello M, Wozniak J, et al. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. American Journal of Psychiatry, 2007.PMID 17898346